Merge Medical Startup Podcast

Stated as a matter of fact, cybersecurity is a big f*^&%ing deal. Join us in a Deep Dive version of the Merge Medical podcast as Dr. Jeff Brown and Dr. Jeff Cole interview Dr. Jose Bolanos. Dr. Bolanos is founder and CEO of Nimbus-T Global and offers a compelling opportunity for enterprise and individuals alike to protect themselves in a world full of bad actors. Cybersecurity threats can hit home in so many ways. Unfortunately, the medical profession and healthcare industry seem to be like fish in a barrel. Constant threats, frequent losses...and few, if any, wins. In addition to high profile ransomware attacks such as Change Healthcare and Ascension, there are countless direct attacks on medical practices. One of these attacks can easily bankrupt a successful, long standing medical practice. With billion-dollar market cap companies trying to create meaningful solutions and put a notch in the win column, is it possible that a physician holds the keys to one of the most revolutionary solutions in existence? Moving well beyond two-factor authentication (2FA) and multi-factorial authentication (MFA), Nimbus-T Global / Nimbus-Key ID provides the most advanced cybersecurity protection at login to enterprise systems. The Nimbus-Key ID mobile app registers each user with KYC/AI/Biometric verification. The user logs into the mobile app with True User Verification and the system bypasses passwords with dynamically encrypted ID in a QRcode (DE-MFA). This system protects the enterprise login process and the user’s true access. Also, having experience with poor cooperation across the myriad of software systems required for the day-to-day activities of both office-based and hospital-based physicians, much thought has gone into the time efficiency of the hardware-agnostic process. If you have escaped direct cybersecurity threat or loss up to this point, some experts would say that it’s only a matter of time. Tune in to the latest Merge Medical podcast to learn more. ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Welcome to the Merge Medical Podcast, where today’s healthcare innovators and leaders come together to shape tomorrow’s healthcare landscape. In our latest episode, we’re honored to host Dr. Robert Pearl, the former CEO of Kaiser Permanente, a prolific author and a visionary in the fields of AI and healthcare. Dr. Robert Pearl was the CEO of The Permanente Medical Group (Kaiser Permanente) from 1999-2017. In this role he led 12,000 physicians, 42,000 staff and was responsible for the nationally recognized medical care of over 5 million Kaiser Permanente members on the west and east coasts. His newest book, “ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine” debuted as #1 on Amazon’s “New Best Seller” list. All profits from the book go to Doctors Without Borders. He is also the author of “Mistreated: Why We think We’re Getting Good Healthcare—And Why We’re Usually Wrong,” a Washington Post bestseller and “Uncaring: How the Culture of Medicine Kills Doctors and Patients,” published May 2021. Pearl, named one of Modern Healthcare’s 50 most influential physician leaders, serves as a clinical professor of plastic surgery at Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He hosts the popular podcasts Fixing Healthcare and Medicine: The Truth, publishes a newsletter called Monthly Musings on American Healthcare, and is a regular contributor to Forbes. Dr. Pearl received his medical degree from the Yale University School of Medicine and completed his residency at Stanford University. Connect with Dr. Robert Pearl on Twitter @RobertPearlMD, LinkedIn and at his website robertpearlmd.com.

Welcome to the Merge Medical Podcast, where today's healthcare innovators and leaders come together to shape tomorrow's healthcare landscape. In our latest episode, we're honored to host Dr. Harvey Castro, a visionary ER physician, AI healthcare futurist, and prolific author in the field of AI and healthcare. Dr. Castro delves into how artificial intelligence is revolutionizing patient care and physician practices, sharing his journey in developing AI technologies aimed at improving outcomes and building a sustainable future for healthcare professionals. Discover the potential of AI to transform healthcare delivery, enhance patient experiences, and unlock new avenues for private practice growth and wealth creation. This is a must-listen for anyone passionate about the intersection of healthcare and technology, seeking practical insights and inspiration to navigate the challenges and opportunities ahead. Join us as Dr. Harvey Castro leads the way in leveraging AI for a healthier tomorrow. Merge Medical Website: https://mergemedical.org LinkedIn Newsletter: https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7080491988705234946

Beyond being a solid entrant to the DPC (direct primary care space) market, First Primary Care founder, Dr. Geetinder Goyal, and his team are on their way to forming a physician led insurance company that solves for healthcare industry’s terminal illness, the mega-carriers. “10 in 10″ or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Goyal, Founder of First Primary Care. First Primary Care (FPC) grew both its membership and its revenue by more than 100% between 2023 and 2024. The vast majority of the 6000 members have onboarded through self-funded employer plans. These plans are comprised of a vertical stack of solutions designed to optimally benefit the patient, the employer, and the physician care team. While many direct primary care (DPC) businesses are emerging, we are not aware of another DPC company has built a full stack health plan that includes a strong primary care base with integrated partners for cash pay specialists and services, a pharmacy benefit manager, TPAs (third party administrators), PPO network access, stop-loss insurance and distribution through brokers who are becoming more of a benefit advisor. With a focus on price transparency, healthcare can become more stream-lined, and value can be measured. The incentives of the FPC physicians are aligned with that of the patient, health and prevention. The original role of insurance is restored to cover catastrophic issues, and not day-to-day needs. Consistent results show a savings of $200K – $300K for a company with 100 employees. First Primary Care accomplishes this with a tiered service line beginning with a solid foundation of primary care. This base layer represents 65% of care and is free to the patient, without copays or other expenses. Generic prescriptions are free. The second level, 25% of care, is Guided Healthcare and demonstrates price transparency and cash pay by the plan for specialists, imaging, outpatient surgery and more. The final 10% is “Guided to Network” care for hospitalizations, ER visits, or catastrophic events. ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ Timestamps: 03:40 –A STRONG FOUNDATION 06:30 – PRICE TRANSPARENCY 06:45 – TIERED APPROACH 07:28 – SELF-FUNDED EMPLOYERS 08:35 – THE ORIGINAL ROLE OF INSURANCE 11:25 – COST SAVINGS TO EMPLOYERS 15:20 – COST VS VALUE 16:05 – 65% BASE LAYER OF FREE HEALTHCARE 17:45 – GUIDED HEALTHCARE 19:30 – GUIDED TO NETWORK 21:05 – PLAN ADMINISTRATION 24:20 – EMPLOYER’S RISK 26:55 – STOP-LOSS CLAIM FUND SURPLUS 29:55 – WHY NOT REDESIGN INSURANCE? 34:30 – STARTING A PHYSICIAN LED INSURANCE COMPANY 40:50 – THE CHANGING ROLE OF BROKERS 47:18 – TPA (THIRD PARTY ADMINISTRATOR) AS PARTNER 48:55 – PHARMACY SERVICES 54:30 – TEAM 57:25 – RPM (Remote Patient Monitoring) 59:45 – WHO IS YOUR CUSTOMER? 102:15 – GROWTH / NATIONAL FOOTPRINT 103:50 – THE BIG INSURERS: ARE THEY TOO BIG TO FAIL? ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice.

Beyond being a solid entrant to the DPC (direct primary care space) market, First Primary Care founder, Dr. Geetinder Goyal, and his team are on their way to forming a physician led insurance company that solves for healthcare industry’s terminal illness, the mega-carriers. “Deep Dive″ or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Goyal, Founder of First Primary Care. First Primary Care (FPC) grew both its membership and its revenue by more than 100% between 2023 and 2024. The vast majority of the 6000 members have onboarded through self-funded employer plans. These plans are comprised of a vertical stack of solutions designed to optimally benefit the patient, the employer, and the physician care team. While many direct primary care (DPC) businesses are emerging, we are not aware of another DPC company has built a full stack health plan that includes a strong primary care base with integrated partners for cash pay specialists and services, a pharmacy benefit manager, TPAs (third party administrators), PPO network access, stop-loss insurance and distribution through brokers who are becoming more of a benefit advisor. With a focus on price transparency, healthcare can become more stream-lined, and value can be measured. The incentives of the FPC physicians are aligned with that of the patient, health and prevention. The original role of insurance is restored to cover catastrophic issues, and not day-to-day needs. Consistent results show a savings of $200K – $300K for a company with 100 employees. First Primary Care accomplishes this with a tiered service line beginning with a solid foundation of primary care. This base layer represents 65% of care and is free to the patient, without copays or other expenses. Generic prescriptions are free. The second level, 25% of care, is Guided Healthcare and demonstrates price transparency and cash pay by the plan for specialists, imaging, outpatient surgery and more. The final 10% is “Guided to Network” care for hospitalizations, ER visits, or catastrophic events. ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ Timestamps: 03:40 –A STRONG FOUNDATION 06:30 – PRICE TRANSPARENCY 06:45 – TIERED APPROACH 07:28 – SELF-FUNDED EMPLOYERS 08:35 – THE ORIGINAL ROLE OF INSURANCE 11:25 – COST SAVINGS TO EMPLOYERS 15:20 – COST VS VALUE 16:05 – 65% BASE LAYER OF FREE HEALTHCARE 17:45 – GUIDED HEALTHCARE 19:30 – GUIDED TO NETWORK 21:05 – PLAN ADMINISTRATION 24:20 – EMPLOYER’S RISK 26:55 – STOP-LOSS CLAIM FUND SURPLUS 29:55 – WHY NOT REDESIGN INSURANCE? 34:30 – STARTING A PHYSICIAN LED INSURANCE COMPANY 40:50 – THE CHANGING ROLE OF BROKERS 47:18 – TPA (THIRD PARTY ADMINISTRATOR) AS PARTNER 48:55 – PHARMACY SERVICES 54:30 – TEAM 57:25 – RPM (Remote Patient Monitoring) 59:45 – WHO IS YOUR CUSTOMER? 102:15 – GROWTH / NATIONAL FOOTPRINT 103:50 – THE BIG INSURERS: ARE THEY TOO BIG TO FAIL? ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice.

Healthcare has been criticized for its slow adoption of advanced technology, and independent doctors can lag even further behind the curve due to the reasonable fear of the financial, security, and administrative risks associated with implementing new and unproven technologies such as AI, digital therapeutics, and remote vital sign monitoring. The healthcare technology landscape is littered with vendors who don’t always have the physician or patient best-interest in mind. “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Brittany Busse, Co-Founder of ViTel Health. ViTel Health is a technology platform-as-a-service company that is empowering physicians to thrive in independent practice by creating and vetting technology solutions that are proven to improve the lives of physicians and the patients they in their care. ViTel Health was founded by Dr. Brittany Busse and Doug Sumaraga in 2021 with the mission “Happy Physicians, Healthy Patients.” Our current “sick care” system has taken the autonomy of physicians, left us burned out, and has decimated the care of patients. ViTel Health is using technology to turn the sick care system to healthcare system and partnering physicians with health coaches who can offer consistent support to patients struggling with chronic disease. It’s more than Remote Physiologic Monitoring, it’s Tech Enabled Health Coaching, and it gets results. Patients are healthier, staying out of the hospital, and physician practices are thriving with the extra revenue combined with limited administrative work. ViTel Health has created a simple vertically-integrated solutions that handles all of the compliance, hiring, documentation, and billing associated with this billable service, empowering doctors to take better care of patients and earn extra revenue. Beyond cutting edge RPM/CCM services, ViTel Health and the ViTel Health Physician Services Cooperative are committed to empowering the return of the independent physician practice in the US. Our services include an affordable and flexible EHR, cost effective credentialing/contracting, revenue cycle management, malpractice, legal advice, and more. ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Healthcare has been criticized for its slow adoption of advanced technology, and independent doctors can lag even further behind the curve due to the reasonable fear of the financial, security, and administrative risks associated with implementing new and unproven technologies such as AI, digital therapeutics, and remote vital sign monitoring. The healthcare technology landscape is littered with vendors who don’t always have the physician or patient best-interest in mind. “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Brittany Busse, Co-Founder of ViTel Health. ViTel Health is a technology platform-as-a-service company that is empowering physicians to thrive in independent practice by creating and vetting technology solutions that are proven to improve the lives of physicians and the patients they in their care. ViTel Health was founded by Dr. Brittany Busse and Doug Sumaraga in 2021 with the mission “Happy Physicians, Healthy Patients.” Our current “sick care” system has taken the autonomy of physicians, left us burned out, and has decimated the care of patients. ViTel Health is using technology to turn the sick care system to healthcare system and partnering physicians with health coaches who can offer consistent support to patients struggling with chronic disease. It’s more than Remote Physiologic Monitoring, it’s Tech Enabled Health Coaching, and it gets results. Patients are healthier, staying out of the hospital, and physician practices are thriving with the extra revenue combined with limited administrative work. ViTel Health has created a simple vertically-integrated solutions that handles all of the compliance, hiring, documentation, and billing associated with this billable service, empowering doctors to take better care of patients and earn extra revenue. Beyond cutting edge RPM/CCM services, ViTel Health and the ViTel Health Physician Services Cooperative are committed to empowering the return of the independent physician practice in the US. Our services include an affordable and flexible EHR, cost effective credentialing/contracting, revenue cycle management, malpractice, legal advice, and more. ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Loss of autonomy is one of the strongest factors leading to physician burnout and exits from medicine. Are you ready to practice on your own schedule? Interested in a cost-effective hybrid practice with a mix of in-person and virtual patient care visits? Satellite offices? Reality check…long term leasing of real estate makes this impossible. “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Greg Goldmacher (Co-Founder) and Ronak Vyas (CEO) of MedCoShare. MedCoShare is combining co-working space with additional services within a fully scalable membership model that starts with one half day per week and a one-month commitment. Premium support services include ordering of supplies, office staffing and practice marketing. MedCoShare plans to make additional bolt-on services available in 2024-25. These targeted services include billing, revenue cycle management, credentialing, and more. Whether you are part of a sizable group or in solo practice, the MedCoShare membership model makes practicing the way you like a reality. It makes opening a satellite office (or two) cost-effective. MedCoShare has moved well beyond the proof-of-concept stage and has its eye on a national growth strategy. This innovative, flexible, and affordable co-working model is currently available in Pennsylvania and New Jersey. Fresh, modern spaces are planned for more locations on the East Coast, as well as other parts of the US in 2024-25. ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Loss of autonomy is one of the strongest factors leading to physician burnout and exits from medicine. Are you ready to practice on your own schedule? Interested in a cost-effective hybrid practice with a mix of in-person and virtual patient care visits? Satellite offices? Reality check…long term leasing of real estate makes this impossible. “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Greg Goldmacher (Co-Founder) and Ronak Vyas (CEO) of MedCoShare. MedCoShare is combining co-working space with additional services within a fully scalable membership model that starts with one half day per week and a one-month commitment. Premium support services include ordering of supplies, office staffing and practice marketing. MedCoShare plans to make additional bolt-on services available in 2024-25. These targeted services include billing, revenue cycle management, credentialing, and more. Whether you are part of a sizable group or in solo practice, the MedCoShare membership model makes practicing the way you like a reality. It makes opening a satellite office (or two) cost-effective. MedCoShare has moved well beyond the proof-of-concept stage and has its eye on a national growth strategy. This innovative, flexible, and affordable co-working model is currently available in Pennsylvania and New Jersey. Fresh, modern spaces are planned for more locations on the East Coast, as well as other parts of the US in 2024-25. ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Sleep is a wonderful thing…if, and when, you can count on it. The sleep aid business is projected to reach $118B by 2030. Why? Very few things treat the root cause. Will Lumos revolutionize the sleep industry through the ability to strengthen and modulate circadian rhythms, the foundation of sleep? “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Biquan Luo, Ph.D. (CEO and Co-Founder) and Kyle Pfaffenbach, Ph.D. (Performance Nutrition Specialist) of Lumos. Lumos was founded by Stanford scientists specializing in regulating human circadian rhythms, Lumos offers a sleep solution for everyone via its smart sleep mask, cell phone app and patented technology. The positive effects of science-based algorithms for jet lag, sleep disruptions caused by night shifts and everyday falling asleep and staying asleep have been demonstrated by robust clinical studies funded by the US military. Lumos is poised to significantly impact quality of sleep on a large scale with its low COG, cost-effective solution. Might you want to own a small piece of this company whose science is two decades in the making? ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Sleep is a wonderful thing…if, and when, you can count on it. The sleep aid business is projected to reach $118B by 2030. Why? Very few things treat the root cause. Will Lumos revolutionize the sleep industry through the ability to strengthen and modulate circadian rhythms, the foundation of sleep? “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Biquan Luo, Ph.D. (CEO and Co-Founder) and Kyle Pfaffenbach, Ph.D. (Performance Nutrition Specialist) of Lumos. Lumos was founded by Stanford scientists specializing in regulating human circadian rhythms, Lumos offers a sleep solution for everyone via its smart sleep mask, cell phone app and patented technology. The positive effects of science-based algorithms for jet lag, sleep disruptions caused by night shifts and everyday falling asleep and staying asleep have been demonstrated by robust clinical studies funded by the US military. Lumos is poised to significantly impact quality of sleep on a large scale with its low COG, cost-effective solution. Might you want to own a small piece of this company whose science is two decades in the making? ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured. ​

A WalMart type POS technology solution for the multi-billion dollar surgical industry. The Summate Trakker is the first & only scanning solution for ALL products used during a surgery, from both inside and outside the sterile field. Handwritten notes are still the norm? “10 in 10” or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Phil Sayles, Founder and CEO of Summate Technologies. Summate has developed the Trakker™, a revolutionary POU tracking platform that leverages patented microchip tagging technology and workflow-friendly software. The Trakker is the first and only total consumption scanning solution for ALL products used during a surgical procedure, at the true point of use, from both inside and at the edge of the sterile field. The platform also delivers product intelligence and VOIP communication to field staff as well. It deploys two types of highly unique scanning technology. ***** Would this bring value to your medical practice, outpatient surgical center or hospital? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

By going back to the drawing board, has this global team of founders solved for tricuspid regurgitation, the “forgotten valve”? How far will they advance this breakthrough solution before one of the 4 major cardiovascular giants want to own it? “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Frank Ahmann of Triflo Cardiovascular. Tricuspid regurgitation (TR) affects millions of elderly patients and is associated with a significant decrease of quality of life, increased hospitalizations, and impaired survival. Symptomatic severe TR is grossly under-treated. The current leading transcatheter technologies only address a limited segment of the patient population. Southern California - based Triflo Cardiovascular is developing the Tricuspid Flow Optimizer, a minimally invasive valve specifically ideated for TR. The minimalistic design includes an adaptive mini valve and single size transfemoral delivery system. The Optimizer works in tandem with the native valve regardless of its size and shape therefore treating a broader patient population. First successful clinical cases have been completed indicating that the device not only reduces regurgitation, but also supports the global cardiac recovery to improve function, exercise capacity, and quality of life. Triflo Cardiovascular is gearing up to expand clinical studies and move towards future regulatory approval. They are preparing to raise a Series B round of funding. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Can this patented Class I FDA Device featuring a reusable blade and reusable handle make intubation easier, faster, and safer in even the most difficult patients and most challenging environments? “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founders of IntuScope, Charla and Keith Bartozzi. IntuScope was founded to pursue and commercialize a new approach to advance field and clinical intubation techniques, reduce the skill disparity, and improve patient outcomes. IntuScope is a patented Class I FDA Device featuring a reusable blade and reusable handle that utilizes a patient’s own anatomy and two actuating arms to open the airway. IntuScope makes intubation easier, faster, and safer in even the most difficult patients. While the device can be used for any intubation, the initial efforts will be focused on the pre-hospital market. ***** Would this bring value to your practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Ketones are the most pure form of energy that our body makes. Have these former Coca-Cola executives and the original founder created the ultimate multifunctional energy and health drink? “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Udaiyan Jatar (Co-Founder & CEO) and Joseph Motto (President & CFO) of Tecton. Tecton is a multifunctional health drink that is based on a breakthrough in exogenous ketone science. Its proprietary ketone molecule overcomes all the biggest barriers to mainstream adoption of exogenous ketones. It tastes good, it is safe even at very high doses (80-100 per day) for all age groups, and it is affordable. The product was designed to be completely safe and healthy with zero carbs, zero caffeine and it is clean label. This allows Tecton to be consumed for metabolic health at macronutrient levels, and therefore, serves as a foundation for weight management, brain health and physical performance. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured. *****

By going back to the drawing board, has this global team of founders solved for tricuspid regurgitation, the “forgotten valve”? How far will they advance this breakthrough solution before one of the 4 major cardiovascular giants want to own it? “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Frank Ahmann of Triflo Cardiovascular. Tricuspid regurgitation (TR) affects millions of elderly patients and is associated with a significant decrease of quality of life, increased hospitalizations, and impaired survival. Symptomatic severe TR is grossly under-treated. The current leading transcatheter technologies only address a limited segment of the patient population. Southern California - based Triflo Cardiovascular is developing the Tricuspid Flow Optimizer, a minimally invasive valve specifically ideated for TR. The minimalistic design includes an adaptive mini valve and single size transfemoral delivery system. The Optimizer works in tandem with the native valve regardless of its size and shape therefore treating a broader patient population. First successful clinical cases have been completed indicating that the device not only reduces regurgitation, but also supports the global cardiac recovery to improve function, exercise capacity, and quality of life. Triflo Cardiovascular is gearing up to expand clinical studies and move towards future regulatory approval. They are preparing to raise a Series B round of funding. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Is surgical drain management worthy of disruption? SOMAVAC is launching a deep tissue negative pressure device for large flaps (mastectomies and hernia repairs). FDA cleared for seroma prevention. Benefits to the patient & hospital/payor undeniable? “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Esra Roan, PhD and Jane Berz, RN, MSN of SOMAVAC, an early-revenue company launching a deep tissue Negative Pressure Therapy device for large flaps created by plastic and general surgeries such as mastectomies and hernia repairs. The internationally patented SOMAVAC SVS delivers constant negative pressure therapy to effectively remove fluids and hold tissue layers together. The device is FDA cleared for seroma prevention. Early studies indicate earlier removal of surgical drains, which is known to correlate with infection rates, and overall fewer complications when compared to literature. The system is closed with one-click fluid disposal bags and markings eliminating the need to pour fluid in to measuring cup. SOMAVAC helps patients and their families recover with dignity after life-impacting surgeries. Significant savings to the hospital and health systems is projected within the immediate $550M market and $4.5B US addressable market. The closed system of fluid collection also allows SOMAVAC to crossover from the medtech to the biotech space potentially advancing science through the analysis of the seroma fluid collected postoperatively from the surgical site. This also extends the total addressable market to $15B. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

Is surgical drain management worthy of disruption? SOMAVAC is launching a deep tissue negative pressure device for large flaps (mastectomies and hernia repairs). FDA cleared for seroma prevention. Benefits to the patient & hospital/payor undeniable? “10 in 10” or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Esra Roan, PhD and Jane Berz, RN, MSN of SOMAVAC, an early-revenue company launching a deep tissue Negative Pressure Therapy device for large flaps created by plastic and general surgeries such as mastectomies and hernia repairs. The internationally patented SOMAVAC SVS delivers constant negative pressure therapy to effectively remove fluids and hold tissue layers together. The device is FDA cleared for seroma prevention. Early studies indicate earlier removal of surgical drains, which is known to correlate with infection rates, and overall fewer complications when compared to literature. The system is closed with one-click fluid disposal bags and markings eliminating the need to pour fluid in to measuring cup. SOMAVAC helps patients and their families recover with dignity after life-impacting surgeries. Significant savings to the hospital and health systems is projected within the immediate $550M market and $4.5B US addressable market. The closed system of fluid collection also allows SOMAVAC to crossover from the medtech to the biotech space potentially advancing science through the analysis of the seroma fluid collected postoperatively from the surgical site. This also extends the total addressable market to $15B. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

If the NIH and JDRF have given Diatech Diabetes the nod through funding…should this company be on your radar? SmartFusion™ is an infusion set failure detection system licensed as a SaaS algorithm to infusion device manufacturers. “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Diatech Diabetes founders John Wilcox and Luis Blanco. Diatech Diabetes is a medical device company committed to changing the way infusion set failure detection is done with their infusion set failure detection system, SmartFusion™. This is accomplished with a combination of real time data analysis and machine learning. SmartFusion™, is an infusion set failure detection system licensed as software-as-a-service to infusion device manufacturers. SmartFusion™ is an algorithm designed specifically for insulin (and other ambulatory drug delivery) pumps to detect different types of infusion failures not currently detected by insulin pumps on the market. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

If the NIH and JDRF have given Diatech Diabetes the nod through funding…should this company be on your radar? SmartFusion™ is an infusion set failure detection system licensed as a SaaS algorithm to infusion device manufacturers. “10 in 10” or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Diatech Diabetes founders John Wilcox and Luis Blanco. Diatech Diabetes is a medical device company committed to changing the way infusion set failure detection is done with their infusion set failure detection system, SmartFusion™. This is accomplished with a combination of real time data analysis and machine learning. SmartFusion™, is an infusion set failure detection system licensed as software-as-a-service to infusion device manufacturers. SmartFusion™ is an algorithm designed specifically for insulin (and other ambulatory drug delivery) pumps to detect different types of infusion failures not currently detected by insulin pumps on the market. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.